EP Patent

EP2658846A2 — Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof

Assigned to Ardea Biociences Inc · Expires 2013-11-06 · 13y expired

What this patent protects

Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-l-yl)-4 H -l,2,4-triazol- 3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditio…

USPTO Abstract

Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-l-yl)-4 H -l,2,4-triazol- 3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.

Drugs covered by this patent

Patent Metadata

Patent number
EP2658846A2
Jurisdiction
EP
Classification
—
Expires
2013-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Ardea Biociences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.